Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection

References

• Almenawer SA, Badhiwala JH, Alhazzani W, et al. Biopsy versus partial versus gross total resection in older patients with high-grade gliomas: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):868–881. doi:10.1093/neuonc/nou349
   PubMed Web of Science ®Google Scholar
• Yang Y, Yao M, Long S, et al. Prognostic nomograms for primary high-grade gliomas patients in adult: a retrospective study based on the SEER database. Biomed Res Int. 2020;2020:1346340. doi:10.1155/2020/1346340
   PubMed Web of Science ®Google Scholar
• Morshed RA, Young JS, Hervey-Jumper SL, Berger MS. The management of low-grade gliomas in adults. J Neurosurg Sci. 2019;63(4):450–457. doi:10.23736/S0390-5616.19.04701-5
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu R, Zhang Q, et al. Charged particle therapy for high-grade gliomas in adults: a systematic review. Radiat Oncol. 2023;18(1):29. doi:10.1186/s13014-022-02187-z
   PubMed Web of Science ®Google Scholar
• Vargas LA, Fernandez CC, Valera MM, Rodriguez-Boto G. Survival analysis in high-grade gliomas: the role of salvage surgery. Neurologia. 2023;38(1):21–28. doi:10.1016/j.nrleng.2020.04.032
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen Y, Wang L, et al. The clinicopathological features and prognosis of multifocal high-grade gliomas in adults with H3F3A mutation. Neurosciences. 2023;28(1):42–47. doi:10.17712/nsj.2023.1.20220080
   PubMed Web of Science ®Google Scholar
• Du P, Yang X, Shen L, et al. Nomogram model for predicting the prognosis of high-grade glioma in adults receiving standard treatment: a retrospective cohort study. J Clin Med. 2022;12(1):196. doi:10.3390/jcm12010196
   PubMed Web of Science ®Google Scholar
• Alvarez S, Alvarez-Vega MA, Balbin M, et al. Prognostic factors and survival study in high-grade gliomas in the elderly. BRIT J NEUROSURG. 2016;30(3):330–336. doi:10.3109/02688697.2016.1139049
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Suppl 5):v1–v95. doi:10.1093/neuonc/noac202
   PubMedGoogle Scholar
• Mirimanoff RO. High-grade gliomas: reality and hopes. Chin J Cancer. 2014;33(1):1–3. doi:10.5732/cjc.013.10215
   PubMedGoogle Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Murata M. Inflammation and cancer. Environ Health Prev. 2018;23(1):50. doi:10.1186/s12199-018-0740-1
   PubMed Web of Science ®Google Scholar
• Grabowski MM, Sankey EW, Ryan KJ, et al. Immune suppression in gliomas. J Neuro-Oncol. 2021;151(1):3–12. doi:10.1007/s11060-020-03483-y
   PubMed Web of Science ®Google Scholar
• Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neuro-Oncol. 2021;151(1):41–53. doi:10.1007/s11060-020-03448-1
   PubMed Web of Science ®Google Scholar
• Saputra HM, Hidayatullah F, Kloping YP, et al. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in penile cancer: a systematic review and meta-analysis. Ann Med Surg. 2022;81:104335. doi:10.1016/j.amsu.2022.104335
   PubMed Web of Science ®Google Scholar
• Wang TC, An TZ, Li JX, Pang PF. Systemic inflammation response index is a prognostic risk factor in patients with hepatocellular carcinoma undergoing TACE. Risk Manag Healthc P. 2021;14:2589–2600. doi:10.2147/RMHP.S316740
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci. 2021;22(15):8002. doi:10.3390/ijms22158002
   PubMed Web of Science ®Google Scholar
• Sim HW, Morgan ER, Mason WP. Contemporary management of high-grade gliomas. CNS Oncol. 2018;7(1):51–65. doi:10.2217/cns-2017-0026
   PubMedGoogle Scholar
• Zhou Q, Xue C, Ke X, Zhou J. Treatment response and prognosis evaluation in high-grade glioma: an imaging review based on MRI. J Magn Reson Imaging. 2022;56(2):325–340. doi:10.1002/jmri.28103
   PubMed Web of Science ®Google Scholar
• Fang L, Yan FH, Liu C, et al. Systemic inflammatory biomarkers, especially fibrinogen to albumin ratio, predict prognosis in patients with pancreatic cancer. Cancer Res Treat. 2021;53(1):131–139. doi:10.4143/crt.2020.330
   PubMed Web of Science ®Google Scholar
• Uludag SS, Sanli AN, Zengin AK, Ozcelik MF. Systemic inflammatory biomarkers as surrogate markers for stage in colon cancer. Am Surgeon. 2022;88(6):1256–1262. doi:10.1177/0003134821995059
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.024
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33(8):e22964. doi:10.1002/jcla.22964
   PubMed Web of Science ®Google Scholar
• Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121. doi:10.1186/s12876-022-02199-9
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin cancer res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroentero. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89–106. doi:10.1038/s41568-019-0222-9
   PubMed Web of Science ®Google Scholar
• Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108. doi:10.1186/s12943-018-0858-1
   PubMed Web of Science ®Google Scholar
• Bianconi A, Aruta G, Rizzo F, et al. Systematic review on tumor microenvironment in glial neoplasm: from understanding pathogenesis to future therapeutic perspectives. Int J Mol Sci. 2022;23(8):4166. doi:10.3390/ijms23084166
   PubMed Web of Science ®Google Scholar
• Habanjar O, Bingula R, Decombat C, et al. Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int J Mol Sci. 2023;24(4):4002. doi:10.3390/ijms24044002
   PubMed Web of Science ®Google Scholar
• Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859–874. doi:10.1016/j.immuni.2021.01.012
   PubMed Web of Science ®Google Scholar
• Guan Y, Xiong H, Feng Y, et al. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with Abiraterone or enzalutamide: a meta-analysis. Prostate Cancer P D. 2020;23(2):220–231. doi:10.1038/s41391-020-0209-3
   PubMed Web of Science ®Google Scholar
• Zhang CL, Jiang XC, Li Y, et al. Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR. J Ovarian Res. 2023;16(1):36. doi:10.1186/s13048-023-01116-2
   PubMed Web of Science ®Google Scholar
• Mizuno R, Kawada K, Itatani Y, et al. The role of tumor-associated neutrophils in colorectal cancer. Int J Mol Sci. 2019;20(3):529. doi:10.3390/ijms20030529
   PubMed Web of Science ®Google Scholar
• Que H, Fu Q, Lan T, Tian X, Wei X. Tumor-associated neutrophils and neutrophil-targeted cancer therapies. BBA Rev Cancer. 2022;1877:188762.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou H, Xu J, et al. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Lett. 2021;496:134–143. doi:10.1016/j.canlet.2020.09.028
   PubMed Web of Science ®Google Scholar
• Filippelli A, Del GC, Simonis V, et al. Scoping review on platelets and tumor angiogenesis: do we need more evidence or better analysis? Int J Mol Sci. 2022;23(21):13401. doi:10.3390/ijms232113401
   PubMed Web of Science ®Google Scholar
• Marx S, Xiao Y, Baschin M, et al. The role of platelets in cancer pathophysiology: focus on malignant gliomas. Cancers. 2019;11(4):569. doi:10.3390/cancers11040569
   PubMed Web of Science ®Google Scholar
• Chim ST, Sanfilippo P, O’Brien TJ, Drummond KJ, Monif M. Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in gliomas patients. J Neuroimmunol. 2021;361:577754. doi:10.1016/j.jneuroim.2021.577754
   PubMed Web of Science ®Google Scholar
• Qi Z, Cai J, Meng X, et al. Prognostic value of preoperative inflammatory markers among different molecular subtypes of lower-grade gliomas. J Clin Neurosci. 2022;96:180–186. doi:10.1016/j.jocn.2021.10.006
   PubMed Web of Science ®Google Scholar
• He Q, Li L, Ren Q. The prognostic value of preoperative Systemic Inflammatory Response Index (SIRI) in patients with high-grade gliomas and the establishment of a nomogram. Front Oncol. 2021;11:671811. doi:10.3389/fonc.2021.671811
   PubMed Web of Science ®Google Scholar
• He K, Si L, Pan X, et al. Preoperative Systemic Immune-Inflammation Index (SII) as a superior predictor of long-term survival outcome in patients with stage I–II gastric cancer after radical surgery. Front Oncol. 2022;12:829689. doi:10.3389/fonc.2022.829689
   PubMed Web of Science ®Google Scholar
• Le VH, Kha QH, Minh TNT, et al. Development and validation of CT-based radiomics signature for overall survival prediction in multi-organ cancer. J Digit Imaging. 2023;36(3):911–922. doi:10.1007/s10278-023-00778-0
   PubMed Web of Science ®Google Scholar
• Le VH, Kha QH, Hung TNK, et al. Risk score generated from CT-based radiomics signatures for overall survival prediction in non-small cell lung cancer. Cancers. 2021;13(14):3616. doi:10.3390/cancers13143616
   PubMed Web of Science ®Google Scholar